Cancer Therapy
Current challenges in Wilms tumor management identified
Published in Cancer Weekly, November 1st, 2005
According to a study from England, "Wilms' tumor is a renal cancer that predominantly affects children during the first 2 years of life. The continuing success of clinical trials in Wilms tumor patients over the past 30 years has led to an overall survival of 85%, and treatment-related morbidity has been reduced."
"Less-aggressive chemotherapeutic regimes are available for patients with validated good prognostic factors, such as low stage and favorable histology. It is becoming increasingly apparent that treatment can be optimized through stratification of patients...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-11-01)
More Articles from Cancer Weekly
- Anticancer Drugs
TrxR inhibition contributes to cytotoxicity of anticancer compounds - Cancer Risk Factors
Susceptibility to carcinogens increased with early-life exposure - Cancer Therapy
Adjuvant chemotherapy proposed for stage II colorectal cancer - Leukemia
AMN107 performed better as inhibitor of Ph-positive leukemia than imatinib - Paclitaxel
Combination therapy had significant effect on reduction of prostate tumor volume - Alternative Surgery
Median sternotomy proposed as alternate approach to extrapleural pneumonectomy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
